DPP4 and COVID-19: However, Nauck et al. (48) reported some limitations regarding the studies by Mirani et al. and Solerte et al. In conclusion, DPP-4 inhibitors may slow the progression of acute respiratory complications in T2DM patients with COVID-19 (49).